Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Triplebody development process

Georg Fey • 15 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Antibodies SPM-2

Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, discusses the development of the lead triplebody candidate and the manufacturing process. Prof. Fey highlights the catch 42 the team are facing in moving this agent into trials, due to the external effector cells that the therapy utilizes. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Georg Fey

2:03
The benefits of dual-targeting triplebodies
Georg Fey • 15 Mar 2019
3:57
Triplebodies for AML: origin, rationale & development
Georg Fey • 15 Mar 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals